Dopamine Agonists Market Size, Share, Players & Trends by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Dopamine Agonists Market Size Analysis

Global Dopamine Agonists Market Introduction
By Indication
1. Introduction
  1. Indication By Value
2. Parkinson's disease
  1. By Value
3. Restless legs syndrome
  1. By Value
4. Hyperprolactinemia
  1. By Value
5. Others
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Ergot Alkaloids
  1. By Value
3. Non-Ergot Dopamine Agonists
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectable
  1. By Value
4. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Drug Stores & Retail Pharmacies
  1. By Value
4. Other Pharmacies
  1. By Value

North America Market Analysis

Introduction
By Indication
1. Introduction
  1. Indication By Value
2. Parkinson's disease
  1. By Value
3. Restless legs syndrome
  1. By Value
4. Hyperprolactinemia
  1. By Value
5. Others
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Ergot Alkaloids
  1. By Value
3. Non-Ergot Dopamine Agonists
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectable
  1. By Value
4. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Drug Stores & Retail Pharmacies
  1. By Value
4. Other Pharmacies
  1. By Value
U.S.
1. By Indication
  1. Introduction
    1. Indication By Value
  2. Parkinson's disease
    1. By Value
  3. Restless legs syndrome
    1. By Value
  4. Hyperprolactinemia
    1. By Value
  5. Others
    1. By Value
2. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Ergot Alkaloids
    1. By Value
  3. Non-Ergot Dopamine Agonists
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectable
    1. By Value
  4. Others
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Drug Stores & Retail Pharmacies
    1. By Value
  4. Other Pharmacies
    1. By Value
Canada

Europe Market Analysis

Introduction
By Indication
1. Introduction
  1. Indication By Value
2. Parkinson's disease
  1. By Value
3. Restless legs syndrome
  1. By Value
4. Hyperprolactinemia
  1. By Value
5. Others
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Ergot Alkaloids
  1. By Value
3. Non-Ergot Dopamine Agonists
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectable
  1. By Value
4. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Drug Stores & Retail Pharmacies
  1. By Value
4. Other Pharmacies
  1. By Value
U.K.
1. By Indication
  1. Introduction
    1. Indication By Value
  2. Parkinson's disease
    1. By Value
  3. Restless legs syndrome
    1. By Value
  4. Hyperprolactinemia
    1. By Value
  5. Others
    1. By Value
2. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Ergot Alkaloids
    1. By Value
  3. Non-Ergot Dopamine Agonists
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectable
    1. By Value
  4. Others
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Drug Stores & Retail Pharmacies
    1. By Value
  4. Other Pharmacies
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Indication
1. Introduction
  1. Indication By Value
2. Parkinson's disease
  1. By Value
3. Restless legs syndrome
  1. By Value
4. Hyperprolactinemia
  1. By Value
5. Others
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Ergot Alkaloids
  1. By Value
3. Non-Ergot Dopamine Agonists
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectable
  1. By Value
4. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Drug Stores & Retail Pharmacies
  1. By Value
4. Other Pharmacies
  1. By Value
China
1. By Indication
  1. Introduction
    1. Indication By Value
  2. Parkinson's disease
    1. By Value
  3. Restless legs syndrome
    1. By Value
  4. Hyperprolactinemia
    1. By Value
  5. Others
    1. By Value
2. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Ergot Alkaloids
    1. By Value
  3. Non-Ergot Dopamine Agonists
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectable
    1. By Value
  4. Others
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Drug Stores & Retail Pharmacies
    1. By Value
  4. Other Pharmacies
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Indication
1. Introduction
  1. Indication By Value
2. Parkinson's disease
  1. By Value
3. Restless legs syndrome
  1. By Value
4. Hyperprolactinemia
  1. By Value
5. Others
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Ergot Alkaloids
  1. By Value
3. Non-Ergot Dopamine Agonists
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectable
  1. By Value
4. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Drug Stores & Retail Pharmacies
  1. By Value
4. Other Pharmacies
  1. By Value
UAE
1. By Indication
  1. Introduction
    1. Indication By Value
  2. Parkinson's disease
    1. By Value
  3. Restless legs syndrome
    1. By Value
  4. Hyperprolactinemia
    1. By Value
  5. Others
    1. By Value
2. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Ergot Alkaloids
    1. By Value
  3. Non-Ergot Dopamine Agonists
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectable
    1. By Value
  4. Others
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Drug Stores & Retail Pharmacies
    1. By Value
  4. Other Pharmacies
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Indication
1. Introduction
  1. Indication By Value
2. Parkinson's disease
  1. By Value
3. Restless legs syndrome
  1. By Value
4. Hyperprolactinemia
  1. By Value
5. Others
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Ergot Alkaloids
  1. By Value
3. Non-Ergot Dopamine Agonists
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectable
  1. By Value
4. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Drug Stores & Retail Pharmacies
  1. By Value
4. Other Pharmacies
  1. By Value
Brazil
1. By Indication
  1. Introduction
    1. Indication By Value
  2. Parkinson's disease
    1. By Value
  3. Restless legs syndrome
    1. By Value
  4. Hyperprolactinemia
    1. By Value
  5. Others
    1. By Value
2. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Ergot Alkaloids
    1. By Value
  3. Non-Ergot Dopamine Agonists
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectable
    1. By Value
  4. Others
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Drug Stores & Retail Pharmacies
    1. By Value
  4. Other Pharmacies
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Dopamine Agonists Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Teva Pharmaceutical Industries Ltd
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Supernus Pharmaceuticals
Lundbeck A/S
AbbVie Inc.
Novartis AG
Amneal Pharmaceuticals LLC
Reddy’s Laboratories Ltd
Intas Pharmaceuticals Ltd.
GLENMARK PHARMACEUTICALS LTD.
Zydus Group
Hikma Pharmaceuticals PLC
TORRENT PHARMACEUTICALS LTD.
Apotex Inc.
Alto Neuroscience, Inc.
Mylan N.V.
Kyowa Kirin Co., Ltd.
Neurocrine Biosciences, Inc.,
Acorda Therapeutics, Inc.
Acadia Pharmaceuticals Inc.
Hoffmann-La Roche Ltd
Others

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment